In this study, we identified KIAA1429 is a key molecule for predicting the efficacy of neoadjuvant therapy and prognosis in CRC, and found that BRAF can regulate its phosphorylation modification and change its localization, thereby further upregulating the WNT pathway to promote oxaliplatin resistance. The gene discussed is VIRMA; the disease is colorectal carcinoma.